{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:53:35Z","timestamp":1776423215382,"version":"3.51.2"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,10,17]],"date-time":"2003-10-17T00:00:00Z","timestamp":1066348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100010749","name":"Hungarian Medical Research Council (Budapest, Hungary)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010749","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase\u2010B platelet activity was low in this patient. \u00a9 2003 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.10641","type":"journal-article","created":{"date-parts":[[2004,1,21]],"date-time":"2004-01-21T05:01:49Z","timestamp":1074661309000},"page":"107-109","source":"Crossref","is-referenced-by-count":4,"title":["Adverse effects of dopamine potentiation by long\u2010term treatment with selegiline"],"prefix":"10.1002","volume":"19","author":[{"given":"Susan","family":"Holl\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e1lm\u00e1n","family":"Magyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,6]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00216456"},{"key":"e_1_2_7_3_2","first-page":"1260","article-title":"Human triosephosphate isomerase deficiency resulting from mutation of Phe\u2010240","volume":"52","author":"Chang ML","year":"1993","journal-title":"Am J Hum Genet"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0764-4469(00)00128-1"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.19.10362"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.3106"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(63)90211-9"},{"key":"e_1_2_7_8_2","volume-title":"Human genetic diseases: a practical approach","author":"Davies KE","year":"1986"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/01616412.1996.11740370","article-title":"A reproducible assay of polymerase chain reaction to detect trinucleotide repeat expansion of Huntington's disease and senile chorea","volume":"18","author":"Watanabe M","year":"1996","journal-title":"Neurol Res"},{"key":"e_1_2_7_10_2","volume-title":"Molecular cloning: a laboratory manual","author":"Maniatis T","year":"1989"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2000.0061"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410170504"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(00)01568-X"},{"key":"e_1_2_7_14_2","first-page":"75","article-title":"Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action","volume":"48","author":"Olanow CW","year":"1996","journal-title":"J Neural Transm"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-0348-6348-3_6"},{"key":"e_1_2_7_16_2","first-page":"8966","volume-title":"Synaptic pharmaceutical corporation","author":"Borowsky B","year":"2001"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.2000.0280"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/225817a0"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8211186"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(98)00864-7"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10191"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.10641","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.10641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:49:34Z","timestamp":1760953774000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.10641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1002\/mds.10641"],"URL":"https:\/\/doi.org\/10.1002\/mds.10641","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}